Business
from24/7 Wall St.
1 day agoIf Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
Oncology-focused Exelixis shows profitable growth, strong earnings beats, and cash generation, making it a defensive biotech candidate near $50 with potential upside.